Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Complex Generics: Gottlieb Eyes FDA Policy Changes To Speed Approvals

Executive Summary

US agency could reconsider requirement that instructions for use be same for branded and generic products, FDA Commissioner-nominee Scott Gottlieb suggests, while also leaving door open to statutory changes in Hatch-Waxman Act.

Advertisement

Related Content

Policy Prescriptions: Kite's CAR-T; Price And Value Scrutiny; Biosimilars; Manufacturing Missteps
Keeping Track: Zelboraf Takes Breakthrough Path For Rare Blood Disease; Teva Resubmits Generic EpiPen
Mylan Suggests Downside To FDA's Efforts To Improve Generic Drug Review
Mylan’s Generic Advair Delay Gives Leverage To Rivals
Gottlieb Nomination As US FDA Chief Could Signal Changes To Generic Approval Process
Amphastar's Naloxone Nasal Spray Delayed; User Human Factors Study Among FDA Concerns
Carrots and Stick: Biopharma At The White House
Complex ANDAs To Be Allowed Pre-Submission Product Meetings
FDA’s Naloxone Product Approval Standards May See Changes
EpiPen Outrage In Congress Puts Spotlight On FDA Generic Review

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

PS120379

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel